Skip to content
This GLP
Updated September 2026Four rungs, two dose lines

Lttl review

Every line publishes a four-rung prepay ladder, and the low-dose and standard-dose products are priced separately rather than blended.

The verdict

Lttl prices its low-dose semaglutide injection at $149 month to month and publishes the whole prepay ladder beneath it: $129 quarterly, $119 every six months and $109 annually, read August 2026. A separate standard-dose line, up to 2.4mg, runs $99 per four-week fill on auto-refill, where a fifty-two-week block bills $1,068.

Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

Category
GLP-1 telehealth
Molecule
Semaglutide · Tirzepatide
Form
Injection · Oral
Dose pricing
Flat across doses
Injection
From $107/mo
Oral
From $194/mo
Prescription
Required
Compounded
Yes — not FDA-approved

Lttl splits its catalog by dose rather than only by molecule, which is unusual and useful. A low-dose line marketed for tolerability sits beside a standard-dose line going up to 2.4mg, and each carries its own price and its own ladder. Both molecules appear, with tirzepatide described as a low-dose GLP-1 and GIP product on the same ladder as the microdose semaglutide.

  1. Who writes the prescription, and what do they see?

    A prescription precedes dispensing and the service runs remotely. What the pages give a reader instead of clinician detail is dose framing, which is the rarer of the two. Knowing that a line is a low-dose product marketed for tolerability tells a buyer something about what they will be taking. A clinician's name usually does not.

    The prepay ladder is the mechanism the whole service is built around, and Lttl publishes all four rungs rather than advertising the deepest one and leaving the rest to checkout. There is also a first-month special at $119 on the low-dose lines and $149 on the oral, which is a separate device again — it lowers one bill without touching any of the four ongoing rates.

  2. What happens when the dose goes up?

    Lttl states the rate holds at every dose, and the two-line structure is what makes that claim legible. The low-dose product is priced as a low-dose product. A buyer moving to standard dosing moves to the separate $99 line rather than climbing a hidden ladder on the first. The standard line's own note caps it at 2.4mg, so the range each figure covers is stated.

  3. What the price includes

    The month-to-month figure is $149 and the annual rung is $109, so committing a year takes $40 a month off the same product — and the pages show every step between. The oral runs the same shape at $179 month to month down to $139 annually. The standard-dose line is the one to read carefully: $99 per four-week fill is thirteen fills a year, which is why the fifty-two-week block bills $1,068 rather than $1,188.

  4. What it claims, and what it cites

    Every line is a compounded preparation, which places all of them outside the FDA review that an approved product completes before dispensing. The low-dose products are marketed for tolerability rather than for a different clinical effect, and the pages do not claim otherwise.

Where it holds up, and where it does not

  • Strength: All four prepay rungs published
  • Strength: Low-dose and standard-dose priced separately
  • Strength: Rate stated to hold at every dose
  • Strength: The four-week fill cycle is disclosed
  • Limitation: The lowest rung needs a year committed
  • Limitation: Standard line bills thirteen times a year
  • Limitation: First-month special applies once
  • Limitation: No state coverage list is recorded

What the evidence says about this kind of treatment

The assessment above is about Lttl. These are about the drugs it sells, and they are traced to the primary literature.

Right for
A reader who wants to see every prepay rung before choosing a term, and who knows which dose line they need.
Wrong for
A reader who wants a single monthly figure with no term to choose.

How Lttl compares

SellerWho it suitsGo
June HealthReaders who want the escalation priced before enrolling rather than met in month threeSee June Health
Lean MedsA reader deciding between paying month to month and committing a year up front, because both rungs are published side by side.See Lean Meds
Trimi HealthA reader who can pay a year at once, or finance it, and wants the per-month figure to stop moving as the dose rises.See Trimi Health
Compare all providers side by side →

More GLP-1 telehealth sellers reviews: NEUVÉ HealthNextMedsNoBsRxNovaNuvaHealthPallas Health

Sponsored alternative

Synergy Rx

A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form.

Check Synergy Rx availability →

Frequently asked

What is the difference between the $149 and $99 lines?
Dose. The $149 is a low-dose product marketed for tolerability; the $99 is the standard-dose line running up to 2.4mg, billed per four-week fill on auto-refill.
What does the annual plan save?
$40 a month against the month-to-month rate on the low-dose injection, taking $149 down to $109, with $129 quarterly and $119 half-yearly in between.
Why does a year cost $1,068 rather than twelve times $99?
Because the standard line bills per four-week fill, which is thirteen fills across fifty-two weeks. Lttl publishes the block figure rather than leaving the arithmetic to the buyer.
Is Lttl expensive compared with other GLP-1 telehealth sellers?
Lttl publishes a starting figure of $107/mo. Across the 83 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $76 to $299 with a median of $179, which puts Lttl below the median, toward the cheaper end. The other 5 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.
Ruth AlvarezOutcomes writer · Reviewed and last verified September 2026

How this was assessed. The four questions above are answered from Lttl’s own publicly-stated model, against the published editorial methodology. No ratings are fabricated and no first-hand outcomes are claimed. A partnership never changes the assessment — see how we make money.